Direct answer: two companies can both advertise a "₹50,000 investment" for a PCD pharma franchise, and one of them means that's your total cost while the other means that's just one line item on top of several more. The number alone tells you almost nothing until you know exactly what it includes.
The Four Cost Buckets Hiding Inside Most Franchise Quotes
When companies break down PCD franchise investment in full detail, the total typically comes from four separate categories stacking on top of each other:
- A franchise or licensing fee — a payment to the parent company simply for the right to use their brand and distribute their products, commonly ₹10,000 to ₹50,000
- Initial stock purchase — the actual inventory you're buying to sell, commonly ₹50,000 to ₹2,00,000
- Regulatory and legal compliance costs — drug license and registration fees, commonly ₹5,000 to ₹20,000
- Working capital — office setup, staff, transport, and operating costs to actually run the business day to day, commonly ₹50,000 to ₹1,00,000 or more
Add those four together at their low end alone — ₹10,000 + ₹50,000 + ₹5,000 + ₹50,000 — and you're already at ₹1,15,000, well before touching the higher end of any of these ranges. A company quoting just "₹50,000 to start" might be quoting only the stock purchase line, with the other three costs surfacing later once you're already committed.
What "No Setup Fees, No Infrastructure Costs" Actually Means
This is the specific detail worth checking directly with any company before comparing numbers: does their quoted investment range include a separate franchise fee stacked on top, or is it genuinely the full cost? Amplec Healthcare structures its franchise investment at ₹20,000 to ₹2,00,000, covering only the initial stock order — explicitly with no separate setup fees and no infrastructure costs layered on top. That's a meaningfully different structure from a company charging a standalone franchise fee before you've even purchased a single unit of stock.
The practical effect: if two companies both quote "up to ₹2,00,000," but one of them bundles a ₹30,000 franchise fee and ₹15,000 in compliance costs into that figure while calling it "stock investment," you're comparing a ₹2,00,000 all-in cost against what might actually total ₹2,45,000 once every bucket is accounted for elsewhere. The headline number looked identical. The real cost wasn't.
Why This Distinction Matters More at the Low End of the Market
The gap matters most for first-time entrepreneurs working with a tight budget, precisely because a hidden ₹30,000-50,000 franchise fee represents a much larger share of a ₹50,000-1,00,000 total budget than it would for someone investing several lakh into a multi-division product range. At the low end, an unexpected fee doesn't just eat into margin — it can be the difference between having enough capital left to actually stock a workable product range or not.
The Three Questions That Cut Through This Immediately
Rather than comparing headline investment figures across companies, ask each one directly:
| Question | What You're Checking For |
| Is there a separate franchise or licensing fee on top of the stock order? | Confirms whether the quoted number is the total, or just one component |
| Does the quoted range include compliance and registration costs, or are those extra? | Reveals whether ₹5,000-20,000 in regulatory costs is already factored in |
| Is there any infrastructure or setup charge beyond stock and standard drug licensing? | Catches costs disguised as "onboarding" or "setup" fees |
A company willing to answer all three clearly and specifically, in writing, before you commit any money, is telling you something real about how transparently they run their franchise program — a vague or evasive answer to any of these three is worth treating as a red flag on its own.
How to Actually Use This When Comparing Companies
Don't compare the headline investment number at all until you've confirmed what it includes. Instead, ask every company on your shortlist to itemize their full cost breakdown — franchise fee (if any), stock cost, compliance cost, and expected working capital for your first few months — and compare those itemized totals against each other. That's the only way two different companies' numbers actually mean the same thing.
The Bottom Line
The PCD franchise industry doesn't use a standardized way of presenting investment costs, which means a lower headline number isn't automatically a cheaper franchise — it might just be a narrower slice of the real total. Companies that fold everything into one transparent figure, like Amplec Healthcare's ₹20,000 to ₹2,00,000 range covering stock alone with no separate setup or infrastructure charges, make this comparison easier; companies that don't require you to ask the itemized questions above before you can trust the number at all.
For the complete investment breakdown and what's included, see Amplec Healthcare's PCD pharma franchise cost and investment guide directly, or visit Amplec Healthcare to get a specific quote for your target territory.
Sign in to leave a comment.